Published in Blood Weekly, April 27th, 2006
"The development of novel cell-based therapies requires understanding of distinct human hematopoietic stem and progenitor cell populations. We recently isolated reconstituting hematopoietic stem cells (HSCs) by lineage depletion and purification based on high aldehyde dehydrogenase activity (ALDH(hi)Lin-cells).
"Here, we further dissected the ALDH(hi)-Lin-population by selection for CD133, a surface molecule expressed on progenitors from hematopoietic, endothelial, and neural lineages," scientists in the United...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.